NCT04801082 is a Phase 4 clinical trial of Alcohol injection in Malignancy, sponsored by The University of Hong Kong.

Who is sponsoring NCT04801082?

NCT04801082 is sponsored by The University of Hong Kong.

What drugs are being tested in NCT04801082?

Interventions in NCT04801082: Alcohol injection, Radiofrequency Ablation.

What condition does NCT04801082 study?

NCT04801082 studies Malignancy, Pain Management.

Is NCT04801082 still recruiting?

NCT04801082 is currently status unknown. Last updated 17 March 2021.

Last reviewed 2021-03-17 · How we verify

NCT04801082

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endoscopic Ultrasound-Guided Coeliac Plexus Neurolysis for Cancer Pain: Chemical Versus Radiofrequency Ablation

Status unknown Phase 4 Last updated 17 March 2021

What this trial tests

Phase 4 trial testing Alcohol injection in Malignancy in 54 participants. Status unknown.

Timeline

1 March 2021

Primary endpoint
31 January 2024

31 March 2025

Quick facts

Lead sponsor	The University of Hong Kong
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	54
Start date	1 March 2021
Primary completion	31 January 2024
Estimated completion	31 March 2025
Sites	1 location across Hong Kong

Drugs / interventions tested

Alcohol injection
Radiofrequency Ablation

Conditions studied

Malignancy — all drugs for Malignancy →
Pain Management — all drugs for Pain Management →

Sponsor

The University of Hong Kong

Who can join

18 and older, any sex, with Malignancy or Pain Management. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change of pain score
Time frame: 4 weeks after the procedure
change of pain score at 4th week after the procedure (by VAS score)

Sponsor's own description

Many cancer patients suffer from intractable pain and which is often suboptimally controlled by even strong opioid analgesics. Coeliac plexus neurolysis (CPN) is procedure which intended to permanently destroy the nociceptive pathway that transmits the pain caused by the tumour. It can be with different approaches, such as percutaneously guided by fluoroscopy, echo-endoscopically or surgically with endoscopic approach being the more popular one in many centers equipped with echo-endoscopic services. The effect of CPN has been well established by some retrospective series. The overall response rate to CPN ranges from 70-90%, however, the analgesic effect is limited and up to roughly around 3 months. It is believed that the short-lasting analgesic effect is related to incomplete neurolysis by absolute alcohol injection. Recently, radiofrequency ablation (RFA) of coeliac plexus has been introduced as another mode of CPN. So far, only one small single center randomized controlled trial (RCT) suggesting superior performance in favour to CPN using RFA. This result has to be validated and by a RCT with larger sample size. In addition, data concerning the quality of life (QOL) improvement and cost-effectiveness need to be further elucidated. Therefore, the aim of this study is to perform a RCT to look into these issues.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sympathetic nerve blocks for persistent pain in adults with inoperable abdominopelvic cancer.
Nagar SD, Nagar SJ, Jordan V, Dawson J. · · 2024 · cited 2× · PMID 38842054 · DOI 10.1002/14651858.cd015229.pub2

Verify or expand the search:

Other recruiting trials for Malignancy

Currently open trials in the same condition.

NCT06999785 — Assessment of the Impact of Increased Production of Reactive Oxygen Species Produced During Repeated Sessions of Hyperba · NA · recruiting
NCT06789601 — Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository · Phase 1, PHASE2 · recruiting
NCT05761366 — Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor · Phase 2 · recruiting
NCT04991922 — BostonGene-Integrated Genomic Registry (BIGR) · recruiting
NCT04656873 — Immuno-Oncology Database and Bioregistry · active not recruiting

Other The University of Hong Kong trials

Trials by the same sponsor.

NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04801082 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
Last refreshed: 17 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04801082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing